Drugs / SB-423562
SB-423562
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02204579 | Jul 2014 → May 2015 | autosomal dominant hypocalcemia | Shire | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB-423562 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1084513 ↗ |
| Known as | NPSP795 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02204579 ↗ |
| Known as | SB-423562-A | ChEMBL registry synonym — accepted as the source's own label CHEMBL1084513 ↗ |
| Known as | SHP-635 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1084513 ↗ |
| Modality | Small molecule | — CHEMBL1084513 ↗ |
| Route | Intravenous | “during and after the IV infusion of NPSP795.” NCT02204579 ↗ |